Nova Mentis Life Science Scientific Advisory Board


Chairman of Scientific Advisory Board

Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx.

He was a co-founder of Medco Research Inc., a NYSE listed clinical research organization and biotechnology company specializing in adenosine products that was subsequently acquired by King Pharmaceuticals.  Dr. Hausman was also a co-founder of Axonyx, and served in various capacities as President, CEO and Chairman until the company merged into NASDAQ listed Torrey Pines Therapeutics Inc. in 2006.  Dr. Hausman is currently a Director of NuGenerex Biotechnology Corporation and is Chairman of the Board of Directors and Chief Science and Technology Officer of Entia Biosciences Inc.

Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at UCLA Medical Center.  He received his medical degree from New York University School of Medicine.

He is on the Alumni Board of Governors of NYU Grossman School of Medicine.


Dr. Kyle Ambert

Preclinical ASD Study Liaison

Dr. Ambert is currently Director of Data Science at Nike, Inc. and has extensive experience in data analytics, machine learning, artificial intelligence and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.


Dr. Julia Perederiy

Lead Scientist, Strategic Advisor

Specializing in scientific discovery and corporate strategy, Dr. Perederiy holds expertise along the full spectrum of biological innovation, from single-cell analytics to systems-level therapeutics. Julia is an author of multiple peer-reviewed publications, including highly regarded studies on the neurogenetics of autism and brain plasticity in neurodegeneration.

Dr. Perederiy is also an experienced entrepreneur and management consultant, helping biotechnology companies with business planning, market research and fundraising. Dr. Perederiy holds Bachelor’s degrees in Neurobiology and Psychology from the University of California, Berkeley, a Master’s in Technology Entrepreneurship from University of Portland and a PhD in Neuroscience from Oregon Health & Science University.


John Molinaro

John Molinaro is a Board Certified Behaviour Analyst (BCBA) with a Master's degree in Applied Behaviour Analysis, as well as a Bachelor's degree in Psychology. For more than 13 years, Mr. Molinaro has dedicated his life to supporting children, youth and adults challenged with physical and cognitive disabilities.

Since 2015, Mr. Molinaro shifted his efforts primarily towards the autism community and started the Colours of the Spectrum ABA autism clinic in 2018. Mr. Molinaro and his team have supported hundreds of children and families with varying severities of autism through one-on-one behaviour therapy and parent coaching.

Mr. Molinaro continues to be a passionate advocator for the research and use of cannabis and classical psychedelics in the field of mental health. As his passion continues to grow, Mr. Molinaro hopes to one day soon bring the science of psychedelic medicine into the realm of autism intervention.  


Gary R. Harlem

Gary R. Harlem is the founder and CEO of Altucell Biotech, a cellular engineering and biotech company focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of diabetes and other autoimmune and neurodegenerative diseases. He is an accomplished entrepreneur focused on the health and wellness sector, launching several companies in the nutritional supplement and health food markets. 

Mr. Harlem has a degree in Education from Dowling College in New York and began his career as a special education teacher. He became interested in exploring novel treatment strategies for autoimmune diseases when his son was diagnosed with Type 1 diabetes at the age of 10.